Login
$IMCR
$29.71 -$0.23 (0.77%) Live

$IMCR SEC Filings

Filed On Filing
09 Nov 2026 SCHEDULE 13G
06 Nov 2026 10-Q
06 Nov 2026 8-K: Results of Operations and Financial Condition

KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date

07 Oct 2026 SCHEDULE 13G/A
14 Sep 2026 8-K: Regulation FD Disclosure

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year

28 May 2026 Form 4: Ratcliffe Peter John, Director

Granted 27,492 Share Option (Right to Buy)

28 May 2026 Form 4: Peterson Kristine, Director

Granted 27,492 Share Option (Right to Buy)

28 May 2026 Form 4: Pao William, Director

Granted 27,492 Share Option (Right to Buy)

28 May 2026 Form 4: Kaul Siddharth, Director

Granted 27,492 Share Option (Right to Buy)

28 May 2026 Form 4: Herbst Roy Steven, Director

Granted 27,492 Share Option (Right to Buy)

28 May 2026 Form 4: Bell John Irving, Director

Granted 27,492 Share Option (Right to Buy)

27 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 27, 2026, Immunocore Holdings plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the ten resolutions set forth below, each of which were voted on and duly passed on a ...

22 May 2026 144
21 May 2026 144
15 May 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support